Blue Zone Wealth Advisors LLC Acquires New Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Blue Zone Wealth Advisors LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 9,574 shares of the company's stock, valued at approximately $3,958,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after acquiring an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC lifted its stake in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock worth $34,000 after acquiring an additional 60 shares during the period. Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories in the third quarter worth $37,000. Finally, Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth $31,000. Institutional investors own 87.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on IDXX shares. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company's stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 0.4 %

Shares of IDXX traded up $1.90 during trading hours on Thursday, hitting $452.89. The company had a trading volume of 615,712 shares, compared to its average volume of 704,594. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The firm has a fifty day moving average price of $431.19 and a 200-day moving average price of $452.42. The stock has a market capitalization of $37.09 billion, a price-to-earnings ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.